Cambridge, Massachusetts-based Werewolf Therapeutics, an oncology biotherapeutics company, has secured $56 million in Series A financing. MPM Capital and Longwood Fund led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners. In conjunction with the funding, Werewolf Therapeutics has named Dr Daniel J. Hicklin as president and CEO.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.